Results 101 to 110 of about 80,637 (252)

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

BMC Cancer
Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor binimetinib ...
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem   +8 more
doaj   +1 more source

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem, Melissa M. de Meza, Cato D. M. Boreel, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Bart Rikhof, Lieke H. J. Simkens, Marion A. Stevense‐den Boer, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Alfonsus J. M. van den Eertwegh, Michel W. J. M. Wouters   +20 more
wiley   +1 more source

Perioperative nivolumab in resectable lung cancer [PDF]

: BACKGROUND Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC).
Karaseva, Nina, Ito, Hiroyuki, Cornelissen, Robin, Taube, Janis M., Provencio Pulla, Mariano, Sepesi, Boris, Spicer, Jonathan D., Bohnet, Sabine, Awad, Mark M., Cascone, Tina, Tanaka, Fumihiro, Petruzelka, Lubos B., de Muniz Koch, Ludmila Oliveira, Pujol, Jean-Louis, Wu, Lin, He, Jie, Erdmann, Cinthya Coronado, Moiseyenko, Fedor V., Blum, Steven I., Gao, Yang, Kuzdzal, Jaroslaw, Meadows-Shropshire, Stephanie, Havel, Libor, Alexandru, Aurelia, Lu, Shun, Ciuleanu, Tudor-Eliade, Sathyanarayana, Padma, Janssens, Annelies, Watanabe, Yasutaka   +28 more
core   +2 more sources

Advances in Immunological Combination Therapy for Colorectal Cancer

iMetaMed, EarlyView.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu, Rongbo Wen, Tianshuai Zhang, Fuao Cao, Xiaoming Zhu, Liqiang Hao, Wei Zhang, Guanyu Yu   +7 more
wiley   +1 more source

Nivolumab — perspectives in cancer treatment [PDF]

, 2016
Blockade of the immune checkpoint PD-1 is a new and promising strategy for the treatment of advanced cancers. The introduction of nivolumab has improved prognosis in a large group of cancer patients.
Rutkowski, Piotr, Koseła, Hanna; Department of Soft Tissue, Bone Sarcoma and Melanoma, Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland   +1 more
core  

Cost-effectiveness of nivolumab in advanced melanoma : a drug review

, 2021
: Introduction: The immune checkpoint inhibitors, including nivolumab, and targeted agents have dramatically improved the outcome for patients with unresectable advanced melanoma.
Specenier, Pol
core  

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Enhanced peripheral blood mononuclear cell lipid metabolism drives poor immunotherapy response via ferroptotic stress‐induced T cell exhaustion in hepatocellular carcinoma

Interdisciplinary Medicine, EarlyView.
Integrated multi‐omics reveals that CD36‐mediated lipid overload in PBMCs drives T cell exhaustion via sub‐lethal ferroptotic stress and AKT suppression. This systemic metabolic signature serves as a robust predictor of immunotherapy response in HCC, suggesting that modulating lipid metabolism can rescue immune fitness.
Ying Zhu, Zhouyu Ning, Yong Deng, Changjing Huang, Hui Li, Yun Sun, Zhiqiang Meng   +6 more
wiley   +1 more source

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

Journal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu, Brian Longbottom, Hassan Aziz   +2 more
wiley   +1 more source